Cargando…
Dopamine D(2) receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia
Dopamine D(2) receptor occupancy (D(2)RO) is a key feature of all currently approved antipsychotic medications. However, antipsychotic efficacy associated with high D(2)RO is often limited by side effects such as motor disturbances and hyperprolactinemia. Lumateperone (ITI-007) is a first-in-class s...
Autores principales: | Vanover, Kimberly E., Davis, Robert E., Zhou, Yun, Ye, Weiguo, Brašić, James R., Gapasin, Lorena, Saillard, Jelena, Weingart, Michal, Litman, Robert E., Mates, Sharon, Wong, Dean F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333832/ https://www.ncbi.nlm.nih.gov/pubmed/30449883 http://dx.doi.org/10.1038/s41386-018-0251-1 |
Ejemplares similares
-
S44. LUMATEPERONE (ITI-007) FOR THE TREATMENT OF SCHIZOPHRENIA: PLACEBO-CONTROLLED CLINICAL TRIALS AND AN OPEN-LABEL SAFETY SWITCHING STUDY
por: Vanover, Kimberly, et al.
Publicado: (2018) -
F46. LUMATEPERONE (ITI-007): FAVORABLE SAFETY PROFILE IN AN OPEN LABEL SAFETY SWITCHING STUDY FROM STANDARD-OF-CARE ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA
por: Davis, Robert, et al.
Publicado: (2018) -
M205. LONG-TERM SAFETY OF LUMATEPERONE (ITI-007): METABOLIC EFFECTS IN A 1-YEAR STUDY
por: Satlin, Andrew, et al.
Publicado: (2020) -
Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial
por: Correll, Christoph U., et al.
Publicado: (2020) -
The role of lumateperone in the treatment of schizophrenia
por: Syed, Alveena Batool, et al.
Publicado: (2021)